Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: Results of the CROSS study

Guido Grassi, Gino Seravalle, Raffaella Dell'Oro, Fosca Quarti Trevano, Michele Bombelli, Francesco Scopelliti, Anna Facchini, Giuseppe Mancia

Research output: Contribution to journalArticle

181 Citations (Scopus)

Abstract

Objective: The increase in blood pressure that accompanies the obese state is almost invariably associated with alterations in metabolism (insulin resistance and dyslipidaemia) and the neurohumoral profile (activation of the renin-angiotensin system, sympathetic overactivity), which potentiate the cardiovascular risk associated with hypertension. However, debate remains as to the antihypertensive drug on which treatment of obesity-related hypertension should be based. The CROSS (Candesartan Role on Obesity and on Sympathetic System) study was undertaken to examine the antihypertensive, neuroadrenergic, and metabolic effects of an angiotensin II receptor blocker in comparison with a diuretic in obese hypertensive individuals. Methods: In 127 obese hypertensive individuals aged 50,7 ± 5.1 years (mean ± SD), we measured clinic blood pressure, heart rate, plasma glucose, and insulin at rest and during an oral glucose load before and 12 weeks after treatment with either candesartan cilexetil (8-16 mg once daily) or hydrochlorothiazide (HCTZ, 25-50 mg once daily), administered orally in accordance with a double-blind, randomized, placebo-controlled, two-parallel-groups study design. Insulin sensitivity was expressed as insulin resistance index (IRI), calculated as the ratio of the area under the curve (AUC) for glucose to that for insulin. In a subgroup of patients, measurements also included direct microneurographic recording of muscle sympathetic nerve activity (MSNA) in the peroneal nerve. Results: Candesartan cilexetil caused a significant (P <0.01) reduction in both mean blood pressure (from 114.2 ± 5.1 to 99.6 ± 6.0 mmHg) and MSNA (from 51.0 ± 12.3 to 40.4 ± 12.5 bursts per 100 heart beats), and a significant (P

Original languageEnglish
Pages (from-to)1761-1769
Number of pages9
JournalJournal of Hypertension
Volume21
Issue number9
DOIs
Publication statusPublished - Sep 1 2003

Fingerprint

Hydrochlorothiazide
Insulin Resistance
Obesity
Blood Pressure
Glucose
Antihypertensive Agents
Insulin
Hypertension
Muscles
Peroneal Nerve
Angiotensin Receptor Antagonists
Renin-Angiotensin System
Dyslipidemias
Diuretics
Area Under Curve
Heart Rate
Placebos
Therapeutics
candesartan
candesartan cilexetil

Keywords

  • Angiotensin II receptor blockers
  • Diuretics
  • Insulin sensitivity
  • Obesity-related hypertension
  • Renin-angiotensin system
  • Sympathetic nervous system

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology

Cite this

Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals : Results of the CROSS study. / Grassi, Guido; Seravalle, Gino; Dell&apos;Oro, Raffaella; Trevano, Fosca Quarti; Bombelli, Michele; Scopelliti, Francesco; Facchini, Anna; Mancia, Giuseppe.

In: Journal of Hypertension, Vol. 21, No. 9, 01.09.2003, p. 1761-1769.

Research output: Contribution to journalArticle

Grassi, Guido ; Seravalle, Gino ; Dell&apos;Oro, Raffaella ; Trevano, Fosca Quarti ; Bombelli, Michele ; Scopelliti, Francesco ; Facchini, Anna ; Mancia, Giuseppe. / Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals : Results of the CROSS study. In: Journal of Hypertension. 2003 ; Vol. 21, No. 9. pp. 1761-1769.
@article{e8a346651b92455eaef925bfa9e08c81,
title = "Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: Results of the CROSS study",
abstract = "Objective: The increase in blood pressure that accompanies the obese state is almost invariably associated with alterations in metabolism (insulin resistance and dyslipidaemia) and the neurohumoral profile (activation of the renin-angiotensin system, sympathetic overactivity), which potentiate the cardiovascular risk associated with hypertension. However, debate remains as to the antihypertensive drug on which treatment of obesity-related hypertension should be based. The CROSS (Candesartan Role on Obesity and on Sympathetic System) study was undertaken to examine the antihypertensive, neuroadrenergic, and metabolic effects of an angiotensin II receptor blocker in comparison with a diuretic in obese hypertensive individuals. Methods: In 127 obese hypertensive individuals aged 50,7 ± 5.1 years (mean ± SD), we measured clinic blood pressure, heart rate, plasma glucose, and insulin at rest and during an oral glucose load before and 12 weeks after treatment with either candesartan cilexetil (8-16 mg once daily) or hydrochlorothiazide (HCTZ, 25-50 mg once daily), administered orally in accordance with a double-blind, randomized, placebo-controlled, two-parallel-groups study design. Insulin sensitivity was expressed as insulin resistance index (IRI), calculated as the ratio of the area under the curve (AUC) for glucose to that for insulin. In a subgroup of patients, measurements also included direct microneurographic recording of muscle sympathetic nerve activity (MSNA) in the peroneal nerve. Results: Candesartan cilexetil caused a significant (P <0.01) reduction in both mean blood pressure (from 114.2 ± 5.1 to 99.6 ± 6.0 mmHg) and MSNA (from 51.0 ± 12.3 to 40.4 ± 12.5 bursts per 100 heart beats), and a significant (P",
keywords = "Angiotensin II receptor blockers, Diuretics, Insulin sensitivity, Obesity-related hypertension, Renin-angiotensin system, Sympathetic nervous system",
author = "Guido Grassi and Gino Seravalle and Raffaella Dell&apos;Oro and Trevano, {Fosca Quarti} and Michele Bombelli and Francesco Scopelliti and Anna Facchini and Giuseppe Mancia",
year = "2003",
month = "9",
day = "1",
doi = "10.1097/00004872-200309000-00027",
language = "English",
volume = "21",
pages = "1761--1769",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals

T2 - Results of the CROSS study

AU - Grassi, Guido

AU - Seravalle, Gino

AU - Dell&apos;Oro, Raffaella

AU - Trevano, Fosca Quarti

AU - Bombelli, Michele

AU - Scopelliti, Francesco

AU - Facchini, Anna

AU - Mancia, Giuseppe

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Objective: The increase in blood pressure that accompanies the obese state is almost invariably associated with alterations in metabolism (insulin resistance and dyslipidaemia) and the neurohumoral profile (activation of the renin-angiotensin system, sympathetic overactivity), which potentiate the cardiovascular risk associated with hypertension. However, debate remains as to the antihypertensive drug on which treatment of obesity-related hypertension should be based. The CROSS (Candesartan Role on Obesity and on Sympathetic System) study was undertaken to examine the antihypertensive, neuroadrenergic, and metabolic effects of an angiotensin II receptor blocker in comparison with a diuretic in obese hypertensive individuals. Methods: In 127 obese hypertensive individuals aged 50,7 ± 5.1 years (mean ± SD), we measured clinic blood pressure, heart rate, plasma glucose, and insulin at rest and during an oral glucose load before and 12 weeks after treatment with either candesartan cilexetil (8-16 mg once daily) or hydrochlorothiazide (HCTZ, 25-50 mg once daily), administered orally in accordance with a double-blind, randomized, placebo-controlled, two-parallel-groups study design. Insulin sensitivity was expressed as insulin resistance index (IRI), calculated as the ratio of the area under the curve (AUC) for glucose to that for insulin. In a subgroup of patients, measurements also included direct microneurographic recording of muscle sympathetic nerve activity (MSNA) in the peroneal nerve. Results: Candesartan cilexetil caused a significant (P <0.01) reduction in both mean blood pressure (from 114.2 ± 5.1 to 99.6 ± 6.0 mmHg) and MSNA (from 51.0 ± 12.3 to 40.4 ± 12.5 bursts per 100 heart beats), and a significant (P

AB - Objective: The increase in blood pressure that accompanies the obese state is almost invariably associated with alterations in metabolism (insulin resistance and dyslipidaemia) and the neurohumoral profile (activation of the renin-angiotensin system, sympathetic overactivity), which potentiate the cardiovascular risk associated with hypertension. However, debate remains as to the antihypertensive drug on which treatment of obesity-related hypertension should be based. The CROSS (Candesartan Role on Obesity and on Sympathetic System) study was undertaken to examine the antihypertensive, neuroadrenergic, and metabolic effects of an angiotensin II receptor blocker in comparison with a diuretic in obese hypertensive individuals. Methods: In 127 obese hypertensive individuals aged 50,7 ± 5.1 years (mean ± SD), we measured clinic blood pressure, heart rate, plasma glucose, and insulin at rest and during an oral glucose load before and 12 weeks after treatment with either candesartan cilexetil (8-16 mg once daily) or hydrochlorothiazide (HCTZ, 25-50 mg once daily), administered orally in accordance with a double-blind, randomized, placebo-controlled, two-parallel-groups study design. Insulin sensitivity was expressed as insulin resistance index (IRI), calculated as the ratio of the area under the curve (AUC) for glucose to that for insulin. In a subgroup of patients, measurements also included direct microneurographic recording of muscle sympathetic nerve activity (MSNA) in the peroneal nerve. Results: Candesartan cilexetil caused a significant (P <0.01) reduction in both mean blood pressure (from 114.2 ± 5.1 to 99.6 ± 6.0 mmHg) and MSNA (from 51.0 ± 12.3 to 40.4 ± 12.5 bursts per 100 heart beats), and a significant (P

KW - Angiotensin II receptor blockers

KW - Diuretics

KW - Insulin sensitivity

KW - Obesity-related hypertension

KW - Renin-angiotensin system

KW - Sympathetic nervous system

UR - http://www.scopus.com/inward/record.url?scp=0041885190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041885190&partnerID=8YFLogxK

U2 - 10.1097/00004872-200309000-00027

DO - 10.1097/00004872-200309000-00027

M3 - Article

C2 - 12923410

AN - SCOPUS:0041885190

VL - 21

SP - 1761

EP - 1769

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 9

ER -